BRIDGEWATER, N.J.--(BUSINESS WIRE)--Dec. 1, 2005--Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced today that the U.S. Food and Drug Administration (FDA) has accepted its supplemental biologics license application (sBLA) seeking approval for an expanded label for its pediatric oncology product, ONCASPAR, as a first-line therapy for the treatment of patients with acute lymphoblastic leukemia (ALL). Currently, ONCASPAR is indicated for patients with ALL who require L-asparaginase in their treatment regimen, but have developed hypersensitivity to the native forms of L-asparaginase. The Company anticipates that the FDA will take action on the sBLA during the third quarter of 2006.
